ES2062364T3 - Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia. - Google Patents

Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia.

Info

Publication number
ES2062364T3
ES2062364T3 ES90305844T ES90305844T ES2062364T3 ES 2062364 T3 ES2062364 T3 ES 2062364T3 ES 90305844 T ES90305844 T ES 90305844T ES 90305844 T ES90305844 T ES 90305844T ES 2062364 T3 ES2062364 T3 ES 2062364T3
Authority
ES
Spain
Prior art keywords
exposure
rabies
treatment
preparing
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90305844T
Other languages
English (en)
Inventor
Bernhard Dietzschold
Charles E Rupprecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Wistar Institute
Original Assignee
The Wistar Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Wistar Institute filed Critical The Wistar Institute
Application granted granted Critical
Publication of ES2062364T3 publication Critical patent/ES2062364T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA COMBINACION DE ANTICUERPOS MONOCLONALES ES UTIL PARA EL TRATAMIENTO, POR EXPOSICION POSTERIOR, DE MAMIFEROS CONTRA LOS VIRUS DE LA RABIA Y LOS RELACIONADOS CON LA RABIA. LA COMBINACION ES INMUNOREACTIVA FRENTE A LAS GLICOPROTEINAS Y NUCLEOPROTEINAS DEL VIRUS DE LA RABIA, Y ES REACTIVO, POR CRUZAMIENTO, CON LOS VIRUS RELACIONADOS CON LA RABIA DUVENHHAGE Y MOKOLA. EL VIRUS ESPECIFICO QUE NEUTRALIZA LA ACTIVIDAD ES SUPERIOR A LOS SUEROS HIPERINMUNES, ANTIRRABICOS EQUINOS O HUMANOS, Y SERA RECOMENDADO, DENTRO DE POCO, POR LA ORGANIZACION MUNDIAL DE LA SALUD COMO TERAPIA POR EXPOSICION POSTERIOR.
ES90305844T 1989-06-08 1990-05-30 Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia. Expired - Lifetime ES2062364T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36514389A 1989-06-08 1989-06-08

Publications (1)

Publication Number Publication Date
ES2062364T3 true ES2062364T3 (es) 1994-12-16

Family

ID=23437645

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90305844T Expired - Lifetime ES2062364T3 (es) 1989-06-08 1990-05-30 Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia.

Country Status (6)

Country Link
EP (1) EP0402029B1 (es)
AT (1) ATE99958T1 (es)
AU (1) AU626684B2 (es)
CA (1) CA2018508A1 (es)
DE (1) DE69005908T2 (es)
ES (1) ES2062364T3 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4006630A1 (de) * 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
PL2314621T3 (pl) * 2004-05-27 2014-08-29 Crucell Holland Bv Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania
AU2011218689C1 (en) * 2004-05-27 2013-05-30 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
DK2027155T3 (en) 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
WO2008068246A1 (en) 2006-12-05 2008-06-12 Crucell Holland B.V. Liquid anti-rabies antibody formulations
WO2011028961A2 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
US9115187B2 (en) 2010-10-19 2015-08-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Identification of antibodies specific for lyssaviruses and methods of their use
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CA2995109A1 (en) * 2015-08-13 2017-02-16 University Of Massachusetts Human antibodies against rabies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods

Also Published As

Publication number Publication date
EP0402029A3 (en) 1991-02-13
DE69005908T2 (de) 1994-04-28
EP0402029A2 (en) 1990-12-12
AU5686890A (en) 1990-12-13
EP0402029B1 (en) 1994-01-12
CA2018508A1 (en) 1990-12-08
DE69005908D1 (de) 1994-02-24
ATE99958T1 (de) 1994-01-15
AU626684B2 (en) 1992-08-06

Similar Documents

Publication Publication Date Title
AU626684B2 (en) Mouse monoglonal antibodies for post-exposure treatment of rabies
Cox et al. Prophylactic immunization of humans against rabies by intradermal inoculation of human diploid cell culture vaccine
Schumacher et al. Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies.
BG98523A (en) Hla-limited cytotoxic t-lymphocytic (ctl) epitopes of the virus of hepatite b
DK0621898T3 (da) Kimæriske immunogener
ATE101648T1 (de) Expression eines tumorspezifischen antigens eines rekombinanten virusvektors sowie dessen anwendung zur versorgenden oder heilenden behandlung des entsprechenden tumors.
DK0495008T3 (da) Vaccinekonjugat til behandling af fuglesygdomme
Harmon et al. Therapy of murine rabies after exposure: efficacy of polyriboinosinic-polyribocytidylic acid alone and in combination with three rabies vaccines
Kasempimolporn et al. Human immune response to rabies nucleocapsid and glycoprotein antigens
ATE96675T1 (de) Spezifische sekretions-exkretions-antigene von toxoplasma gondii, deren expressionsprodukte, verfahren zu deren herstellung und deren diagnostische und prophylaktische anwendungen.
ATE185073T1 (de) Impfstoff zubereitungen
DE69030099D1 (de) Verfahren zur herstellung von impfstoffen oder toxoiden
DE3853736D1 (de) Staupevirus-Impfstoff.
ATE122100T1 (de) Humaner monoklonaler antikörper und diesen enthaltende arzneimittelzusammensetzung zur behandlung von pseudomonasinfektionen.
Mifune et al. A mouse model for the pathogenesis and postexposure prophylaxis of rabies
ATE132374T1 (de) Verhütung und behandlung einer retrovirenkrankheit
Yoneda et al. Protection of mice from rabies by intranasal immunization with inactivated rabies virus
Vodopija Current issues in human rabies immunization
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
Kreil et al. Passive immunization reduces immunity that results from simultaneous active immunization against tick-borne encephalitis virus in a mouse model
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
DE68918127D1 (de) Peptidbehandlung von hartnäckigen Infektionskrankheiten.
Fuenzalida et al. Production of hyperimmune antirabies serum in horses
RU2006117308A (ru) Фармацевтические композиции для терапевтического применения
ATE126704T1 (de) Bcrf1-antagonisten zur behandlung von epstein- barr-virus-infektionen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 402029

Country of ref document: ES